KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases: 2018-2024

Historic Operating Leases for Moderna (MRNA) over the last 7 years, with Dec 2024 value amounting to $671.0 million.

  • Moderna's Operating Leases fell 3.29% to $677.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $677.0 million, marking a year-over-year decrease of 3.29%. This contributed to the annual value of $671.0 million for FY2024, which is 4.35% up from last year.
  • As of FY2024, Moderna's Operating Leases stood at $671.0 million, which was up 4.35% from $643.0 million recorded in FY2023.
  • Moderna's 5-year Operating Leases high stood at $671.0 million for FY2024, and its period low was $92.0 million during FY2022.
  • For the 3-year period, Moderna's Operating Leases averaged around $468.7 million, with its median value being $643.0 million (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first dropped by 13.21% in 2022, then surged by 598.91% in 2023.
  • Yearly analysis of 5 years shows Moderna's Operating Leases stood at $97.0 million in 2020, then rose by 9.28% to $106.0 million in 2021, then declined by 13.21% to $92.0 million in 2022, then spiked by 598.91% to $643.0 million in 2023, then rose by 4.35% to $671.0 million in 2024.